India markets open in 6 hours 54 minutes
  • BSE SENSEX

    52,653.07
    +209.36 (+0.40%)
     
  • Nifty 50

    15,778.45
    +69.05 (+0.44%)
     
  • Dow

    35,084.53
    +153.60 (+0.44%)
     
  • Nasdaq

    14,778.26
    +15.68 (+0.11%)
     
  • BTC-INR

    2,949,033.00
    -30,024.25 (-1.01%)
     
  • CMC Crypto 200

    935.12
    +4.76 (+0.51%)
     
  • Hang Seng

    26,315.32
    +841.44 (+3.30%)
     
  • Nikkei

    27,782.42
    +200.76 (+0.73%)
     
  • EUR/INR

    88.2847
    +0.0260 (+0.03%)
     
  • GBP/INR

    103.6579
    +0.0678 (+0.07%)
     
  • AED/INR

    20.1700
    -0.0690 (-0.34%)
     
  • INR/JPY

    1.4713
    -0.0012 (-0.08%)
     
  • SGD/INR

    54.8940
    -0.0470 (-0.09%)
     

Goldfinch Bio to Present at the Raymond James Human Health Innovation Conference

·1-min read

CAMBRIDGE, Mass., Jun 14, 2021--(BUSINESS WIRE)--Goldfinch Bio, a clinical stage biotechnology company focused on discovering and developing precision medicines for the treatment of kidney diseases, today announced that Anthony Johnson, M.D., Chief Executive Officer of Goldfinch Bio, will present a corporate overview at the Raymond James Human Health Innovations Conference on Monday, June 21, 2021 at 9:20 a.m. ET.

About Goldfinch Bio

Goldfinch Bio, Inc. is a clinical stage biotechnology company focused on delivering disease-modifying precision medicines that bring hope and renewed quality of life to people living with kidney diseases. We aspire to save kidneys and end dialysis. Our precision medicine product engine allows us to discover and validate novel targets aimed at understanding the molecular and phenotypic heterogeneity in diverse kidney disease patient populations to identify subsets most likely to respond to our treatments. We have a robust pipeline of novel, precision medicine product candidates targeting kidney diseases with significant unmet need, including two clinical-stage assets. In 2020, Goldfinch Bio was named one of Fierce Biotech’s "Fierce 15" companies. Visit us at www.goldfinchbio.com to learn more.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210614005050/en/

Contacts

Goldfinch Bio Contacts:

Investors:
Hannah Deresiewicz
Stern Investor Relations, Inc.
212-362-1200
hannah.deresiewicz@sternir.com

Media:
Liz Melone
lmelone@goldfinchbio.com

Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting